ArticleQuantitative imaging in medicine and surgery2026
Dynamic fluorine-18 fluorodeoxyglucose PET for evaluating different-sized metastatic lymph nodes in patients with non-small cell lung cancers.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: For patients with non-small cell lung cancer (NSCLC), accurate and detailed lymph node (LN) staging is crucial for treatment planning and prognosis. However, reliably distinguishing metastatic from nonmetastatic LNs remains a clinical challenge, especially in small-sized LNs. A retrospective study was conducted to evaluate the ability of dynamic fluorine-18 fluorodeoxyglucose (F-18 FDG) positron emission tomography (PET), specifically the metabolic parameter of net influx rate (Ki), in distinguishing metastatic from and nonmetastatic LNs of different sizes in patients with NSCLC. Methods: In the study, 366 patients with lung nodules or masses detected on chest computed tomography (CT) scan underwent dynamic chest F-18 FDG PET/CT and static whole-body F-18 FDG PET/CT imaging after providing informed consent. A retrospective collection of 369 LNs in 98 patients with NSCLC was pathologically confirmed. CT features [density, maximum short diameter (D Results: Among the 369 LNs, 172 were metastatic, and 197 were nonmetastatic. The CT features, static PET features, and Ki were significantly different between the metastatic and nonmetastatic LNs (P<0.05). The AUCs of D Conclusions: Compared with static PET features and CT features, the dynamic PET parameter Ki demonstrated superior diagnostic performance in differentiating metastatic from nonmetastatic LNs, particularly in the group of small LNs. After optimization of the cutoff value, the Ki improved the clinical applicability in identifying metastatic LNs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.